An inexpensive, well-tolerated traditional plant with a clean safety record. The most consistent human signals are faster fracture healing and less bone pain, plus modest drops in body weight, blood sugar, and cholesterol. Broader bone, joint, and longevity claims rest mainly on animal work. Overall evidence quality is low; side effects are mild and short-lived. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting blood glucose | 75–86 mg/dL | Tracks the metabolic benefit and guards against additive lowering |
| HbA1c | < 5.4% | Average blood sugar over ~3 months; confirms durable metabolic change |
| Lipid panel (LDL, HDL, triglycerides) | LDL < 100 mg/dL; HDL > 50 mg/dL; triglycerides < 90 mg/dL | Captures the cholesterol/triglyceride changes seen in trials |
| Body weight / waist circumference | Waist < 94 cm (men), < 80 cm (women) | Primary endpoint for weight/metabolic goals |
| Serum calcium | 9.2–10.0 mg/dL | Safety and bone context, especially if co-supplementing calcium |
| Alkaline phosphatase (ALP) | 40–90 U/L | Bone-formation marker for bone-healing goals |
| Parathyroid hormone (PTH) | 15–45 pg/mL | The one bone marker meta-analysis found the plant raises |
| 25-hydroxy vitamin D | 40–60 ng/mL | Vitamin D underpins any bone benefit |
| Platelet count | 150–400 ×10⁹/L | Screens for the rare low-platelet signal from a case report |
| ALT / AST | ALT < 25 U/L (men), < 20 U/L (women) | General safety check for any long-term botanical |
Cadence: Baseline before first dose, re-check relevant markers at about 8–12 weeks, then every 6–12 months if use continues; more frequent blood-sugar checks for anyone on diabetes medication